Misperceptions and stereotypes about opioid dependence that may affect how it's treated have persisted among the general public and physicians despite increased attention devoted to the issue, according to a new survey.
The Annals of Internal Medicine published a study comparing generic utilization of common diabetes medications across two government programs — Medicare Part D and the U.S. Department of Veterans Affairs.
The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.
At the 2013 Business and Leadership Conference in Orlando, Fla., HDMA honored pharmaceutical and consumer product manufacturers during the presentation of the 2013 Distribution Industry Awards for Notable Achievements in Healthcare.
There are several important pieces of legislation that will have an impact on the business of supermarket pharmacy if passed, noted Michael Spira, American Pharmacists Association senior lobbyist, during an FMI education session.
Out of all retail pharmacy outlets, food stores have slightly increased their prescription sales, generating March year-to-date sales of $5.7 billion, up 0.5%, according to IMS Health data. Including drug, mail and independents, prescription sales totaled $58.3 billion, down 4.7%, reported Doug Long, VP industry relations for IMS Health, at an FMI education breakout.
The Food and Drug Administration last month announced that it has approved an amended application submitted by Teva Women's Health to market Plan B One-Step (levonorgestrel) for use without a prescription by women 15 years of age and older. That approval moved Plan B One-Step from behind the pharmacy counter into the family planning section of the pharmacy.
The year is only halfway done, but 2013 is already proving to be a year of particular importance for generic drugs as the industry awaits two important decisions from the Supreme Court and continues to wait for federal biosimilar regulations while fending off efforts to limit the scope of their use at the state level.